Search

Zucapsaicin

Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. … Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain.

Bitolterol

Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

Racemethionine

A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

Sodium molybdate

Luspatercept

[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin

Hydracarbazine

Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

Dextropropoxyphene

The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

DL-dimyristoylphosphatidylglycerol

DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

Mometasone

Mometasone is a corticosteroid not currently used in medical products. Mometasone furoate however, is still in use.

Clorazepic acid

In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.